查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1546208

子宮癌治療與診斷的全球市場

Uterine Cancer Therapeutics and Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球子宮癌藥物和診斷市場預計將達到 282 億美元

子宮癌藥物和診斷的全球市場預計 2023 年為 214 億美元，預計到 2030 年將達到 282 億美元，在 2023-2030 年分析期間複合年成長率為 4.0%。子宮內膜癌治療和診斷是本報告分析的細分市場之一，預計複合年成長率為 4.9%，到分析期結束時將達到 190 億美元。在分析期間，子宮肉瘤治療和診斷領域的複合年成長率估計為 2.4%。

美國市場預估57億美元，中國預估年複合成長率7.5%

到 2023 年，美國子宮癌藥物和診斷市場預計將達到 57 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達64億美元，2023-2030年分析期間複合年成長率為7.5%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 1.3% 和 4.6%。在歐洲，德國的複合年成長率預計為 1.7%。

全球子宮癌治療和診斷市場 - 主要趨勢和促進因素總結

為什麼子宮內膜癌的檢測和治療很重要？

子宮內膜癌是影響女性最常見的癌症之一，主要包括子宮內膜癌和子宮肉瘤。早期發現和有效治療對於提高生存率和生活品質至關重要。隨著全球子宮內膜癌發生率的增加，對先進治療和診斷試劑的需求也增加。透過經經陰道超音波、子宮內膜切片檢查和先進影像方式等技術進行早期檢測可以顯著改善治療結果。此外，手術、放射線治療、化療和荷爾蒙療法等個人化治療方法正在不斷發展，以針對特定的癌症類型和階段，改善患者的治療效果並最大限度地減少副作用。分子診斷和生物標記測試的整合進一步提高了客製化治療的能力，確保患者根據腫瘤的基因組成獲得最有效的治療。

科技進步如何徹底改變子宮內膜癌的治療？

技術創新對於推進子宮內膜癌的診斷和治療至關重要。機器人輔助手術等微創手術技術的出現縮短了恢復時間並改善了手術結果，為患者提供了創傷較小、併發症較少的選擇。此外，標靶治療和免疫療法的發展開闢了新的治療途徑，特別是對於晚期和復發性子宮內膜癌患者。透過標靶參與癌症生長的特定分子，這些治療方法可以實現更精確、更有效的治療，並且比傳統化療副作用更少。在診斷方面，次世代定序儀(NGS) 和液態切片正在成為識別基因突變和即時監測治療反應的強大工具。這些進步將使臨床醫生能夠做出更明智的決定，根據需要調整治療，並提供更個人化的照護。

是什麼推動了子宮內膜癌先進診斷和治療方法的採用？

子宮內膜癌的盛行率不斷上升，特別是在老年族群和具有生活方式相關危險因子的人群中，導致我們正在推廣先進的診斷和治療方法。隨著人們對子宮內膜癌症狀和早期檢測重要性的認知不斷提高，越來越多的女性正在接受定期篩檢，從而實現早期診斷並改善治療結果。此外，醫療保健提供者擴大採用個人化醫療方法，利用基因和分子測試來幫助指導治療決策。越來越多的研究支持這種向精準醫學的轉變，這些研究將特定基因突變與子宮內膜癌的治療效果聯繫起來。此外，已開發和新興市場醫療保健支出的增加使人們能夠獲得先進的診斷和治療，有助於提高存活率和患者的治療效果。包括腫瘤科醫生、放射科醫生、病理學家和遺傳諮詢師在內的多學科護理團隊的作用不斷擴大，也正在加強為子宮內膜癌患者提供全面和協調的護理。

推動子宮癌藥物和診斷市場成長的因素有哪些？

子宮癌治療和診斷市場的成長受到多種因素的推動，包括診斷技術的進步、個人化治療選擇的數量增加以及全球子宮內膜癌盛行率的上升。分子診斷和生物標記主導治療的開發正在取得進展，這些創新透過實現更有針對性和有效的治療策略，為市場擴張做出了重大貢獻。此外，人們越來越重視透過定期檢查和使用先進影像技術進行早期發現，從而增加了對診斷服務的需求。人們對子宮內膜癌的認知不斷提高以及及時介入的重要性也推動了患者對最先進治療和診斷的需求。此外，已開發市場和新興市場不斷成長的醫療保健支出使得這些先進技術能夠更廣泛地獲得，進一步推動市場成長。最後，包括標靶治療和免疫療法在內的不斷擴大的新療法將繼續主導市場，因為這些療法為晚期和抗藥性子宮內膜癌患者帶來了新的希望，預計將發揮主導作用。

受訪企業範例（46家知名企業）

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP15408

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$28.2 Billion by 2030

The global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$21.4 Billion in the year 2023, is expected to reach US$28.2 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030. Endometrial Carcinomas Therapeutics and Diagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Uterine Sarcomas Therapeutics and Diagnostics segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uterine Cancer Therapeutics and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Uterine Cancer Detection and Treatment So Vital?

Uterine cancer, one of the most common cancers affecting women, primarily includes endometrial cancer and uterine sarcomas. Early detection and effective treatment are critical for improving survival rates and quality of life. As the incidence of uterine cancer rises globally, the demand for advanced therapeutics and diagnostics has intensified. Early-stage detection through techniques like transvaginal ultrasound, endometrial biopsy, and advanced imaging methods can significantly improve treatment outcomes. Moreover, personalized treatment approaches, including surgery, radiation therapy, chemotherapy, and hormone therapy, have evolved to target specific cancer types and stages, improving patient outcomes and minimizing side effects. The integration of molecular diagnostics and biomarker testing has further refined the ability to tailor treatments, ensuring that patients receive the most effective therapies based on the genetic makeup of their tumors.

How Are Technological Advancements Revolutionizing Uterine Cancer Care?

Technological innovations have been pivotal in advancing both the diagnosis and treatment of uterine cancer. The advent of minimally invasive surgical techniques, such as robotic-assisted surgery, has reduced recovery times and improved surgical outcomes, offering patients less invasive options with fewer complications. Additionally, the development of targeted therapies and immunotherapies has opened new avenues for treatment, particularly for patients with advanced or recurrent uterine cancer. These therapies work by targeting specific molecules involved in cancer growth, allowing for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. On the diagnostics front, next-generation sequencing (NGS) and liquid biopsies are emerging as powerful tools for identifying genetic mutations and monitoring treatment responses in real-time. These advancements enable clinicians to make more informed decisions, adjust treatments as needed, and provide more personalized care.

What Is Driving the Adoption of Advanced Diagnostics and Therapeutics in Uterine Cancer?

The increasing prevalence of uterine cancer, particularly in aging populations and those with lifestyle-related risk factors, is driving the adoption of advanced diagnostics and therapeutics. As awareness of uterine cancer symptoms and the importance of early detection grows, more women are undergoing regular screenings, leading to earlier diagnosis and better treatment outcomes. Additionally, healthcare providers are increasingly adopting personalized medicine approaches, utilizing genetic and molecular testing to guide treatment decisions. This shift towards precision medicine is supported by the growing body of research linking specific genetic mutations to treatment responses in uterine cancer. Furthermore, the rising healthcare expenditures in developed and emerging markets are enabling greater access to advanced diagnostics and treatments, contributing to improved survival rates and patient outcomes. The expanding role of multidisciplinary care teams, including oncologists, radiologists, pathologists, and genetic counselors, is also enhancing the delivery of comprehensive and coordinated care for uterine cancer patients.

What Factors Are Driving the Growth in the Uterine Cancer Therapeutics and Diagnostics Market?

The growth in the Uterine Cancer Therapeutics and Diagnostics market is driven by several factors, including advancements in diagnostic technologies, the increasing availability of personalized treatment options, and the rising prevalence of uterine cancer worldwide. The ongoing development of molecular diagnostics and biomarker-driven therapies is significantly contributing to market expansion, as these innovations allow for more targeted and effective treatment strategies. Additionally, the growing emphasis on early detection through regular screenings and the use of advanced imaging techniques is increasing the demand for diagnostic services. The rising awareness of uterine cancer and the importance of timely intervention are also driving patient demand for cutting-edge therapies and diagnostics. Furthermore, the increasing healthcare expenditure in both developed and emerging markets is enabling broader access to these advanced technologies, further fueling market growth. Finally, the expanding pipeline of new therapeutics, including targeted therapies and immunotherapies, is expected to continue driving the market as these treatments offer new hope for patients with advanced or resistant forms of uterine cancer.

Select Competitors (Total 46 Featured) -

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Uterine Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Uterine Cancer Driving Demand forg Advanced Therapeutics
    • Rising Adoption of Personalized Medicine in Cancer Treatment
    • Advancements in Genomic Testing Enhancing Early Diagnosis Capabilities
    • Growing Demand for Minimally Invasive Surgical Techniques
    • Development of Targeted Therapies Creating New Market Opportunities
    • Impact of Aging Population on Uterine Cancer Incidence
    • Increasing Investments in Cancer Research and Development
    • Adoption of AI and Machine Learning in Diagnostic Technologies
    • Rising Awareness and Screening Programs Boosting Early Detection Rates
    • Growing Demand for Combination Therapies in Cancer Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Uterine Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • INDIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AFRICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION